HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)

China · Delayed Price · Currency is CNY

3.560

-0.140 (-3.78%)

Sep 10, 2026, 2:40 PM CST

Market Cap	8.25B +5.3%
Revenue (ttm)	2.04B -11.9%
Net Income	401.47M +65.8%
EPS	0.18 +68.9%
Shares Out	2.23B
PE Ratio	20.50
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	282,550,402
Open	3.700
Previous Close	3.700
Day's Range	3.500 - 3.700
52-Week Range	2.370 - 5.100
Beta	0.17
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About SHE:002437

HARBIN GLORIA PHARMACEUTICALS Co., LTD, together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China and internationally. The company offers cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamin supplements, electrolyte drugs, hypoglycemic drugs, analgesics, digestive system and metabolic drugs, anti-infective drugs, and anti-tumor drugs. It also provides deer antler polypeptide injections, Annao pills and tablets, potassium chloride su... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2000

Employees 2,350

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 002437

Full Company Profile

Financial Performance

In 2025, SHE:002437's revenue was 2.14 billion, a decrease of -12.51% compared to the previous year's 2.44 billion. Earnings were 376.91 million, an increase of 61.93%.

Financial Statements